Detalhe da pesquisa
1.
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
N Engl J Med
; 384(16): 1529-1541, 2021 04 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-33882206
2.
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
N Engl J Med
; 380(8): 741-751, 2019 02 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30786188
3.
Repeated adjuvant anti-CEA radioimmunotherapy after resection of colorectal liver metastases: Safety, feasibility, and long-term efficacy results of a prospective phase 2 study.
Cancer
; 123(4): 638-649, 2017 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27763687
4.
Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.
Cancer
; 123(19): 3843-3854, 2017 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28558150
5.
Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE).
Ann Rheum Dis
; 80(7): 954-955, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33619162
6.
Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia.
Haematologica
; 101(11): 1327-1332, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27515248
7.
Optimization of Dual-Labeled Antibodies for Targeted Intraoperative Imaging of Tumors.
Mol Imaging
; 14: 348-55, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26162516
8.
The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.
Br J Haematol
; 169(5): 701-10, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25847298
9.
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers.
Bioconjug Chem
; 26(5): 919-31, 2015 May 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-25915780
10.
Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab.
Blood
; 122(17): 3020-9, 2013 Oct 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-23821660
11.
Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug.
Mol Pharm
; 12(6): 1836-47, 2015 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25402018
12.
Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2.
Pediatr Blood Cancer
; 62(7): 1171-5, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25732247
13.
Trop-2-targeting tetrakis-ranpirnase has potent antitumor activity against triple-negative breast cancer.
Mol Cancer
; 13: 53, 2014 Mar 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-24606732
14.
Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006.
Rheumatology (Oxford)
; 53(3): 502-11, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24273022
15.
Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas.
Blood
; 119(16): 3767-78, 2012 Apr 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-22271448
16.
Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma.
Haematologica
; 99(11): 1738-45, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25150258
17.
Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer.
Eur J Nucl Med Mol Imaging
; 41(8): 1593-602, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24643780
18.
¹8F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma.
Eur J Nucl Med Mol Imaging
; 41(8): 1501-10, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24806110
19.
Al(18) F labeling of peptides and proteins.
J Labelled Comp Radiopharm
; 57(4): 219-23, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24408125
20.
Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas.
Oncotarget
; 15: 144-158, 2024 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38386805